Teva Launches Generic Version of Syprine in the US
14 February 2018 - - Petach Tikva, Israel-based generic and specialty medicines company Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) (TASE: TEVA) has launched a generic version of Syprine (trientine hydrochloride) capsules, 250 mg, in the US, the company said.
Trientine hydrochloride is used in the treatment of penicillamine-intolerant patients with Wilson's disease, a genetic disease that prevents the body from removing excess copper and potentially causing life-threatening organ damage.
Clinical experience with trientine hydrochloride is limited and alternate dosing regimens have not been well-characterized; all endpoints in determining an individual patient's dose have not been well defined.
Trientine hydrochloride and penicillamine cannot be considered interchangeable. Trientine hydrochloride should be used when continued treatment with penicillamine is no longer possible because of intolerable or life endangering side effects.
Teva is a patient-centric healthcare solutions, and generic and specialty medicines producer.
It leverages its portfolio of more than 1,800 molecules to produce a range of generic products in nearly every therapeutic area.
In specialty medicines, the company has an innovative treatment for multiple sclerosis as well as late-stage development programmes for other disorders of the central nervous system, including movement disorders, migraine, pain and neurodegenerative conditions, as well as a portfolio of respiratory products.